9 HRT Myths That Persist Among Doctors and Why They Harm Patients
There is something particularly exhausting about being denied a treatment by the very person you trusted to help you — especially when the reason they give turns out to be based on flawed data from a study that ended over twenty years ago. So many women have spent years being told their symptoms were 'just aging' when what they actually needed was someone to look at the updated evidence. That is the reason this page exists.
Learn more about Rose →"HRT causes breast cancer" — the myth that launched a generation of undertreated women
The 2002 WHI trial found a small absolute increase in breast cancer risk in the combined estrogen-progestogen arm — roughly 8 extra cases per 10,000 women per year — a risk smaller than that associated with drinking one glass of wine daily or being overweight. Critically, the estrogen-only arm of the same trial showed a statistically significant reduction in breast cancer risk. The original press release catastrophised a relative risk number without context, and that framing has outlasted the corrected science by two decades.
"HRT causes heart attacks" — a conclusion drawn from the wrong population at the wrong time
The WHI enrolled women with a mean age of 63, many of whom were overweight, sedentary, and years past menopause — a population in which starting oral estrogen does carry cardiovascular caution. When HRT is initiated in women under 60 or within ten years of menopause onset, the data consistently show neutral to cardioprotective effects, a principle now known as the timing hypothesis or the window of opportunity. Treating a 51-year-old with hot flashes the same as a 63-year-old with pre-existing cardiovascular disease is not evidence-based medicine.
"You should only use HRT for the shortest time at the lowest dose" — a guideline without a proper evidence base
This phrase, repeated in consulting rooms worldwide, originated not from a clinical trial but from a cautious regulatory position adopted in the aftermath of the WHI panic. There is no trial evidence establishing that five years of HRT is safer than ten, or that a lower dose is meaningfully safer than a therapeutic dose — and for many women, long-term use is precisely what protects their bone density, cardiovascular health, and cognitive function. Major menopause societies including the British Menopause Society and the Menopause Society now explicitly state that duration should be individualised, not arbitrarily capped.
"Bioidentical hormones are safer than conventional HRT" — a marketing claim dressed as medicine
The term bioidentical is not a pharmacological classification — it is a marketing term, and when used to promote compounded preparations, it exists almost entirely outside the regulatory frameworks that ensure consistent dosing and safety monitoring. Regulated transdermal estradiol and micronised progesterone are structurally identical to the hormones the body produces and have a strong evidence base behind them; unregulated compounded preparations do not. Patients seeking body-identical hormones already have access to them through standard prescribing channels.
"Progesterone and progestins are the same thing" — a distinction that genuinely changes the risk profile
Synthetic progestins — such as medroxyprogesterone acetate used in the WHI — have a different receptor binding profile to micronised progesterone and do not behave identically in the body. The observational E3N cohort study, involving over 80,000 women, found that the combination of transdermal estradiol with micronised progesterone was not associated with increased breast cancer risk over five years, unlike combinations using synthetic progestins. A doctor who conflates all progestogens when discussing risk is working from an oversimplification that may lead to unnecessarily withholding treatment.
"Hot flashes are just uncomfortable — HRT is a lifestyle choice, not a medical need"
Vasomotor symptoms are not merely an inconvenience: severe and persistent hot flashes are associated with disrupted sleep architecture, increased cardiovascular risk markers, reduced bone mineral density, and significant cognitive burden. The framing of HRT as optional or cosmetic — reserved for women who simply cannot cope — has been described by menopause researchers as a form of medical minimisation that would be unlikely to persist if the patient population were different. Symptom severity is a legitimate clinical indicator, not a measure of a woman's tolerance threshold.
"HRT is not appropriate for women with a family history of breast cancer"
A family history of breast cancer is not, on its own, a contraindication to HRT under current evidence-based guidelines from the British Menopause Society or the International Menopause Society. Risk assessment should be individualised based on the nature of the family history, genetic testing results where available, and the woman's personal risk-benefit calculation — and that conversation requires an informed clinician, not a blanket policy. Women carrying BRCA mutations require specialist input, but the majority of women with a relative who had breast cancer are not in the same risk category.
"Symptoms that started years after periods stopped are not hormone-related"
Estrogen receptors exist throughout the brain, cardiovascular system, bones, urogenital tract, and skin, and their response to declining estrogen does not follow a neat timeline tied to the last menstrual period. Many women experience the onset or worsening of joint pain, genitourinary symptoms, mood instability, and cognitive difficulties several years into postmenopause — all of which have a plausible hormonal mechanism. Dismissing late-onset symptoms as unrelated to menopause because the transition happened years ago is not supported by the physiology.
"HRT should be stopped at 60" — an age cut-off with no clinical trial basis
No trial has demonstrated that ceasing HRT at age 60 produces better outcomes than continuing it in a healthy woman who is benefiting from treatment; the age limit appears to have emerged from an overly cautious extrapolation of WHI data, in which the average age of participants happened to be 63. The 2022 NICE menopause guideline update and the Menopause Society both affirm that there is no arbitrary age at which HRT must stop, and that ongoing benefit — particularly for bone and cardiovascular health — can extend well into the sixties and beyond when risk factors are reviewed regularly. Women in their late fifties or sixties being told to stop simply because of age are not receiving individualised care.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.